MedTrace Logo

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled HH-120 Aerosol in Healthy Volunteers

NCT05116865 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2023-09-26

No results posted yet for this study

Summary

This is a Phase 1, randomized, double-blinded, placebo controlled, dose escalation study of HH-120 in healthy adult volunteers. HH-120 is a novel inhalable biologic being developed for COVID-19 treatment. The study aims to evaluate the safety, tolerability and pharmacokinetic profile of HH-120 administered by aerosol inhalation after single and multiple ascending doses.

Conditions

  • COVID-19 Respiratory Infection

Interventions

BIOLOGICAL

HH-120 Dose 1

Dose level 1 of HH-120

BIOLOGICAL

HH-120 Dose 2

Dose level 2 of HH-120

BIOLOGICAL

HH-120 Dose 3

Dose level 3 of HH-120

DRUG

Placebo

Placebo to match

Sponsors & Collaborators

  • Huahui Health

    lead INDUSTRY

Principal Investigators

  • Yongqing Lin · Huahui Health Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2022-05-26
Completion
2022-08-02

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05116865 on ClinicalTrials.gov